Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
71,858,757
-
Total 13F shares
-
10,293,731
-
Share change
-
+7,259,410
-
Total reported value
-
$375,364,173
-
Price per share
-
$6.47
-
Number of holders
-
9
-
Value change
-
+$39,325,578
-
Number of buys
-
7
Institutional Holders of SINOVAC BIOTECH LTD. - Common Shares (SVA) as of Q2 2025
As of 30 Jun 2025,
SINOVAC BIOTECH LTD. - Common Shares (SVA) was held by
9 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,293,731 shares.
The largest 9 holders included
Vivo Capital, LLC, ORBIMED ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, Neumann Advisory Hong Kong Ltd, WELLS FARGO & COMPANY/MN, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MORGAN STANLEY, UBS Group AG, and Horizon Investments, LLC.
This page lists
9
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.